Public health expertise
At the forefront of public health, we leverage our expertise to deliver the most robust evidence for transformative healthcare solutions.
Our clients trust us for our professionalism, reliability, and exceptional quality in health economics, market access, health simulation modeling, and strategic public and medical affairs. When we join a project, we become a dedicated part of the teamâpartners, not just consultants.
Founded and led by medical doctors specializing in public health, PHE is driven by a singular mission: to improve public health. Itâs not just what we doâitâs who we are.
Key figures
PHE was initially founded in 2012 by Dr Martin Blachier and Dr Henri Leleu with a simple vision: offering academic-level public health expertise to the private sector reliably and efficiently. Our continued existence proves our success.
Our multidisciplinary team includes highly trained consultants including MDs, Pharm. D – MPH, PhDs, as well as experienced managers. We value scientific and technical expertise in our consultants.
We have concluded over 200 missions both for the public and private sector covering every aspects of public health from prevention & screening to assessing breakthrough therapies though improving patients’ experience.
Our simulation model team has successfully constructed over 20 disease simulation models to extrapolate epidemiological trends, assess cost-effectiveness or estimate the impact of innovations.
We have assisted the pharmaceutical industry in submitting over 30 dossiers to the French authorities to ensure patients’ access to treatment and negotiate fair prices.
We proud ourselves in successfully achieving every mission. Our client success in improving public health is our success, and the reason for our continued existence.
Associates & Collaborators
Dr. Martin Blachier
Dr Martin Blachier (MD, MPH, MBA) has more than 15 years of experience in market access, innovation development, public health and epidemiology. He has previously worked at HAS, the Ministry of Health and for many international organizations. Since 2012, he has supported public health actors and private companies with their projects in France and Europe.
Dr. Henri Leleu
Dr Henri Leleu (MD, MPH, PhD) is an medical doctor specialized in public health and holds a PhD in health economics. He has over 15 years in public health in the fields of epidemiology, health economy, health care organization, health innovation and methodology. He is an expert in health care simulations with over 20 simulation models developed in wide range of dieases.
Quentin Berkovitch
Health Simulation Lead Programmer
Quentin Berkovitch (MSc) is the lead Health Simulation Programmer at Public Health Expertise. His role involves the development and implementation of intricate health simulation model. He is proficient in applying data science to healthcare challenges. Quentin's experience makes him adept at handling complex projects within both French and broader European contexts.
Jérémy Carette
HEOR Director
Jérémy Carette (PharmD, MSc) serves as a senior consultant specializing in health economic evaluation, as well as pricing and reimbursement strategies. With a six-year track record in consulting, he has spearheaded and executed numerous successful projects, catered to both France and European contexts. Collaborating with public authorities, experts, and international teams, his work spans a broad spectrum of medical indications.
Alexandre Vimont
Real World Data Director
Alexandre Vimont (PhD, MSc) is an expert in Real World Evidence (RWE) generation, biostatistics and statistical modelling. Over a 10-year experience in consulting, he has carried out and overseen RWE evidence studies based on the SNDS and medical registries in collaboration with clinical experts in several therapeutic areas. He is actually conducting a PhD for developing prognosis models with AI approach based on SNDS data.
Solenn
Le Clanche
International Medical Director
Solenn Le Clanche has a PhD in biochemistry and cellular biology. She has been working in an academic research laboratory at the Faculty of Pharmacy in Paris for 7 years and in a Medical Education company for 4 years. She is an expert in international practice survey, expertsâ consensus, medical writing and medical education programs.
Sophie Fertat
Director of Business Development & Marketing
Sophie FERTAT has a PhD in physiology and a specialization in clinical development of health products. She has been working in business development and marketing dedicated to health stakeholders since 2012, in service provider environment. Her mission is to support and optimize PHE's growth by leveraging her network, technical and market knowledge.
Yann
Le Goff
Strategy and Patient Pathways Director
Yann Le Goff has a master degree in pharmaceutical management. He has been working in consulting dedicated to health stakeholders since 2008. He is an expert of qualitative studies, patient pathways optimization and data crunching. His mission is to help the different business units (marketing, medical, business intelligence, etc.) to design the most appropriate strategy.
Clients & Partners
INDUSTRIES
companies
Public health expertise has created PHESim
PHESim is the health simulation model arm of public health expertise. PHESim is dedicated to develop and create high-end health simulation models including microsimulation and agent-based model for the health care sector. With the help of SimLab, the health simulation R&D unit at PHESim, public health expertise can offer the full power of health simulation model to its client. Predicting long term cost-effectiveness of innovation, estimating future epidemiological trends, comparing treatment strategies, projecting sales based on strategic decisions or convincing decision makers to invest in innovation are some of the issues where public health expertise can produce evidence for its clients.
Medical Affairs & Medical Education by PHE
PHE Med was created in 2021, and its mission is to develop tailor-made solutions to solve your medical problems. Through its core business, we have built up a large network of quickly mobilized KOLs as well as strong medical expertise that allow us to respond with relevance and in depth to your needs.
Publications
20 décembre 2021Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program
BarrĂ©, S., H. Leleu, R. Benamouzig, J. C. Saurin, A. Vimont, S. Taleb, and F. De Bels. 2020. ‘Cost-effectiveness analysis of alternative colon cancer screening strategies in the context ofâŠ
20 décembre 2021SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia
Gallo, A., S. Charriere, A. Vimont, M. J. Chapman, D. Angoulvant, F. Boccara, B. Cariou, V. Carreau, A. CarriĂ©, E. Bruckert, and S. BĂ©liard. 2020. ‘SAFEHEART risk-equation and cholesterol-year-score areâŠ
20 décembre 2021A stochastic agent-based model of the SARS-CoV-2 epidemic in France
Hoertel, N., M. Blachier, C. Blanco, M. Olfson, M. Massetti, M. S. Rico, F. Limosin, and H. Leleu. 2020. ‘A stochastic agent-based model of the SARS-CoV-2 epidemic in France’, NatâŠ
20 décembre 2021Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France
Leeuwenkamp, O., J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier, and T. Walter. 2020. ‘Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients withâŠ
20 décembre 2021Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals
Benamouzig, R., S. BarrĂ©, J. C. Saurin, H. Leleu, A. Vimont, S. Taleb, and F. De Bels. 2021. ‘Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals’, TherapâŠ
20 décembre 2021Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals
BĂ©raud, G., J. C. Maupetit, A. Darras, A. Vimont, and M. Blachier. 2021. ‘Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals’, Infect Dis Ther.
20 décembre 2021The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia
Gallo, A., L. PĂ©rez de Isla, S. CharriĂšre, A. Vimont, R. Alonso, O. Muñiz-Grijalvo, J. L. DĂaz-DĂaz, D. ZambĂłn, P. Moulin, E. Bruckert, P. Mata, and S. BĂ©liard. 2021. ‘TheâŠ
20 décembre 2021Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France
Vimont, A., H. Leleu, and I. Durand-Zaleski. 2021. ‘Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France’, EurâŠ
7 septembre 2021A survey of patient blood management for patients undergoing cardiac surgery in nine European countrie
Klein A, Agarwal S, Cholley B, Fassl J, Griffin M, Kaakinen T, Mzallassi Z, Paulus P, Rex S, Siegemund M, van Saet A. A survey of patient blood management forâŠ
7 septembre 2021Impact of the timing and adherence to face mask use on the course of the COVID-19 epidemic in France
Hoertel N, Blachier M, SĂĄnchez-Rico M, Limosin F, Leleu H. Impact of the timing and adherence to face mask use on the course of the COVID-19 epidemic in France. JâŠ
7 septembre 2021Evaluation of the PRADO home discharge support programme for orthopaedic surgery in 2018
Luu, V. P., A. Vimont, H. Leleu, V. Mace, T. Mondschein, E. Haushalter, A. Laborde, H. Akkari, F. X. Brouck, and A. Fouchard. 2021. ‘Evaluation of the PRADO home dischargeâŠ
Adresse
10 boulevard de SĂ©bastopol
75004 Paris
Tel
Contact